Tyche Wealth Partners LLC Purchases Shares of 8,335 CRISPR Therapeutics AG (NASDAQ:CRSP)

Tyche Wealth Partners LLC purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 8,335 shares of the company’s stock, valued at approximately $328,000.

A number of other institutional investors have also recently made changes to their positions in CRSP. Bank of Montreal Can grew its position in shares of CRISPR Therapeutics by 26.3% in the 2nd quarter. Bank of Montreal Can now owns 7,556 shares of the company’s stock valued at $408,000 after buying an additional 1,574 shares during the last quarter. Creative Planning grew its position in shares of CRISPR Therapeutics by 3.2% in the 2nd quarter. Creative Planning now owns 14,750 shares of the company’s stock valued at $797,000 after buying an additional 456 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of CRISPR Therapeutics by 4.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after buying an additional 211 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at about $381,000. Finally, Exchange Traded Concepts LLC lifted its stake in shares of CRISPR Therapeutics by 22.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock valued at $902,000 after purchasing an additional 3,563 shares during the period. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the topic of a number of recent analyst reports. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. HC Wainwright initiated coverage on CRISPR Therapeutics in a research note on Monday. They issued a “buy” rating and a $65.00 price objective on the stock. Barclays dropped their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Finally, JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $77.59.

CRISPR Therapeutics Stock Down 3.8 %

Shares of CRISPR Therapeutics stock opened at $40.61 on Friday. The company has a market cap of $3.47 billion, a PE ratio of -14.35 and a beta of 1.67. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10. The business has a 50 day moving average price of $43.20 and a 200-day moving average price of $46.82.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the company posted ($1.41) earnings per share. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.1 EPS for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.